Effects of fendiline on cocaine-seeking behavior in the rat
- 335 Downloads
L-type Ca2+ channels (LTCC) and GABAB receptors are both possible targets in the development of new pharmacological compounds for cocaine addiction. Drugs that target either receptor attenuate a wide range of cocaine-seeking behaviors in the rat. However, there is no current human-approved pharmacotherapeutic intervention for psychostimulant addiction.
This study examined the effects of a human-approved LTCC blocker, fendiline, on cocaine-taking and cocaine-seeking behavior in rats. The effects of combining fendiline with the GABAB receptor agonist baclofen on cocaine self-administration were also tested.
Male Wistar rats were trained to self-administer cocaine, and the effects of fendiline pretreatment (vehicle, 1.78, 3.16, 5.62 mg/kg, intraperitoneal (IP)) were tested on progressive ratio responding and cue- and drug-induced reinstatement. The effects of baclofen (vehicle, 0.56, 1.78, 3.16, 5.62 mg/kg, IP) combined with fendiline (5.62 mg/kg, IP) were tested on progressive ratio responding. Control experiments measured locomotor activity and lever pressing for food in rats that received both baclofen and fendiline prior to the test session.
Acute injections of fendiline prior to cue- or drug-induced reinstatement significantly attenuated lever-pressing behavior (p < 0.05). Fendiline and baclofen, but not fendiline alone, not only significantly attenuated breakpoints, but also impaired general motor behavior and naturalistic reinforcement (p < 0.05).
These data suggest that the LTCC blocker fendiline may represent a novel pharmacotherapeutic intervention to prevent reinstatement to cocaine seeking. Also, co-administration of fendiline and baclofen not only can attenuate the motivation to take cocaine, but also impairs general motor behavior and naturalistic reinforcement.
KeywordsAddiction Cocaine Self-administration Reinstatement L-type calcium channel antagonist GABAB receptor Fendiline
The authors would like to thank Anthony Phillips for his comments and suggestions in the preparation of this article. This research was supported by CFI/NSRIT #17561, NSHRF MED-Project-2008-4695, and St FX UCR #91642.
Conflict of interest
There are no conflicts of interest to report.
- Bayer R, Mannhold R (1986) Fendiline: a review of its basic pharmacological and clinical properties. Pharmatherapeutica 5:103–136Google Scholar
- Biala G (2002) Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol 55:327–335Google Scholar
- Cryan JF, Kelly PH, Chaperon F et al (2004) Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N, N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310:952–963CrossRefPubMedGoogle Scholar
- Licata SC, Schmidt HD, Pierce RC (2004) Suppressing calcium/calmodulin-dependent protein kinase II activity in the ventral tegmental area enhances the acute behavioural response to cocaine but attenuates the initiation of cocaine-induced behavioural sensitization in rats. Eur J Neurosci 19:405–414CrossRefPubMedGoogle Scholar
- Lynch WJ, Nicholson KL, Dance ME, Morgan RW, Foley PL (2010) Animal models of substance abuse and addiction: implications for science, animal welfare, and society. Comparative Med 60:177–188Google Scholar
- Roberts DCS, Goeders N (1989) Drug self-administration: experimental methods and determinants. In: Boulton AA, Baker GB, Greenshaw AJ (eds) Neuromethods: psychopharmacology. Humana Press Inc., Clifton NJ, pp 439–398Google Scholar